Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21963757 | 0.88 | EGFR (0.33) | KMT2AMEN1LMNAGAA | |
| SCHEMBL25707381 | 0.88 | LMNA (0.39) | KMT2AMEN1ALDH1A1LMNAGAA | |
| SCHEMBL22010512 | 0.87 | GBA1 (0.34) | KMT2AMEN1LMNAGAAHDAC1 | |
| SCHEMBL24923371 | 0.84 | ESR1 (0.32) | GAAESR1ESR2 | |
| SCHEMBL21963733 | 0.80 | KMT2A (0.46) | KMT2AMEN1 | |
| SCHEMBL22010747 | 0.79 | ESR1 (0.38) | KMT2AGAAESR1ESR2 | |
| SCHEMBL21964000 | 0.78 | MAOA (0.37) | KMT2AMEN1ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL21963701 | 0.77 | TOP2A (0.36) | KMT2AMEN1ALDH1A1GAAHPGD | |
| SCHEMBL29958536 | 0.76 | GAA (0.34) | GAA | |
| SCHEMBL28604517 | 0.74 | ESR2 (0.39) | ALDH1A1LMNAGAANPSR1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159519-A1 | NOVEL COMPOUNDS AND THEIR USE | DEBIOPHARM INTERNATIONAL S.A. (CH) | 2023-05-25 | — | — | US | disclosed |
| US-20230035837-A1 | ANTIBIOTIC COMPOUNDS, METHODS OF MANUFACTURING THE SAME, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND USES THEREOF | DEBIOPHARM INTERNATIONAL S.A. (CH) | 2023-02-02 | — | — | US | disclosed |
| EP-4077324-A1 | NOVEL COMPOUNDS AND THEIR USE | Debiopharm International SA (CH) | 2022-10-26 | — | — | EP | disclosed |
| EP-3880675-A1 | ANTIBIOTIC COMPOUNDS, METHODS OF MANUFACTURING THE SAME, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND USES THEREOF | Debiopharm International SA (CH) | 2021-09-22 | — | — | EP | disclosed |
| WO-2021123372-A1 | NOVEL COMPOUNDS AND THEIR USE | DEBIOPHARM INTERNATIONAL S.A. (CH) | 2021-06-24 | — | — | WO | disclosed |
| WO-2020099341-A1 | ANTIBIOTIC COMPOUNDS, METHODS OF MANUFACTURING THE SAME, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND USES THEREOF | DEBIOPHARM INTERNATIONAL S.A. (CH) | 2020-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159519-A1 | NOVEL COMPOUNDS AND THEIR USE | LSS, PGLS, LDHB | KMT2A 275/4885MEN1 4447/4885ALDH1A1 1885/4885 |
| US-20230035837-A1 | ANTIBIOTIC COMPOUNDS, METHODS OF MANUFACTURING THE SAME, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND USES THEREOF | GMPS, GNE, GANC | KMT2A 3401/4885MEN1 585/4885ALDH1A1 1858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.